Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,371 across all filing types
Latest filing 2025-11-03 Board/Management Inform…
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
(1) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR&#x3b; (2) RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR&#x3b; AND (3) CHANGE IN COMPOSITION OF BOARD COMMITTEES
Board/Management Information Classification · 1% confidence The document is a corporate announcement detailing the appointment and resignation of independent non-executive directors and changes in the composition of board committees. It specifically relates to changes in the company’s board of directors and committee roles, which falls under Board/Management Information (MANG).
2025-11-03 English
ANNOUNCEMENT ON RESULTS OF THE ISSUANCE OF THE 2025 SECOND TRANCHE OF SCI-TECH INNOVATION BONDS
Capital/Financing Update Classification · 1% confidence The document is an official announcement under Hong Kong Exchange listing rules detailing the results of the company’s bond issuance, including issued amount, coupon rate, bookrunners, and underwriter details. This is a financing update on the issuance of debt instruments, fitting the Capital/Financing Update category.
2025-10-30 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 1% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2025-10-30 English
RESULTS REPORT FOR THE THIRD QUARTER OF 2025
Interim / Quarterly Report Classification · 1% confidence The document is a 'Results Report for the Third Quarter of 2025' for Yankuang Energy Group. It contains detailed financial statements, including balance sheets, income statements, and cash flow data for the reporting period. It is a comprehensive quarterly financial report rather than a mere announcement or summary, fitting the definition of an Interim/Quarterly Report (IR). Q3 2025
2025-10-30 English
OVERSEAS REGULATORY ANNOUNCEMENT NOTICE OF RESULTS PRESENTATION FOR THE THIRD QUARTER OF 2025
Investor Presentation Classification · 1% confidence The document is an announcement under Hong Kong Listing Rule 13.10B, providing details (time, dial-in, participants) for the Company’s results presentation—i.e., an investor conference call/webcast—for Q3 2025. It contains logistics for an upcoming event and does not present any financial metrics or the report itself. This fits the Investor Presentation category rather than an earnings release (which would include key financial highlights) or a transcript (which would be the verbatim call text).
2025-10-28 English
VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING BY CEO AND EXECUTIVE DIRECTOR DR. JIANXIN YANG AND SENIOR MANAGEMENT BY 1,000,000 SHARES
Director's Dealing Classification · 1% confidence The announcement details insider purchases of the company’s shares by the CEO and senior management, disclosing personal acquisitions and changes in shareholding by directors/executives. This matches the definition of Director’s Dealing (insider transactions).
2025-10-23 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.